[1]胡见英.血浆BNP、PDW与RDW联合测定诊断慢性心力衰竭的价值[J].医学信息,2021,34(02):174-176.[doi:10.3969/j.issn.1006-1959.2021.02.049]
　HU Jian-ying.The Value of Combined Determination of Plasma BNP,PDW and RDW in the Diagnosis of Chronic Heart Failure[J].Medical Information,2021,34(02):174-176.[doi:10.3969/j.issn.1006-1959.2021.02.049]
点击复制

血浆BNP、PDW与RDW联合测定诊断慢性心力衰竭的价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年02期
页码:
174-176
栏目:
诊疗技术
出版日期:
2021-01-15

文章信息/Info

Title:
The Value of Combined Determination of Plasma BNP,PDW and RDW in the Diagnosis of Chronic Heart Failure
文章编号:
1006-1959（2021）02-0174-03
作者:
胡见英
（东莞市寮步医院检验科，广东 东莞 523401）
Author(s):
HU Jian-ying
(Department of Laboratory Medicine,Liaobu Hospital,Dongguan 523401,Guangdong,China)
关键词:
慢性心力衰竭; B型钠尿肽; 红细胞分布宽度; 血小板分布宽度
Keywords:
Chronic heart failure; B-type natriuretic peptide; Red blood cell distribution width; Platelet distribution width
分类号:
R541.61
DOI:
10.3969/j.issn.1006-1959.2021.02.049
文献标志码:
A
摘要:
目的 探讨血浆BNP、PDW与RDW联合测定诊断慢性心力衰竭的价值。方法 选择2019年8月~2020年7月我院收治的慢性心力衰竭患者100例作为研究组，根据美国纽约心脏病协会（NYHA）心功能分级分为Ⅱ级组（42例）、Ⅲ级组（36例）、Ⅳ级组（22例），遵循1:1匹配原则选择100名同期来我院体检的健康志愿者作为对照组，比较各组血浆BNP、PDW、RDW水平，分析其与慢性心力衰竭患者心功能分级的相关性。结果 研究组血浆BNP、PDW、RDW水平均高于对照组，差异有统计学意义（P＜0.05）；Ⅱ级组、Ⅲ级组、Ⅳ级组血浆BNP、PDW、RDW水平比较，差异有统计学意义（P＜0.05）。Pearson相关性分析，血浆BNP、PDW、RDW水平与慢性心力衰竭患者心功能分级呈正相关（r=0.861、0.584、0.474，P<0.05）。结论 血浆BNP、PDW、RDW水平与慢性心力衰竭患者心功能分级呈正相关，随着慢性心力衰竭患者心功能分级增高而呈递增趋势，在慢性心力衰竭患者诊断、病情及心功能评估中具有一定的价值。
Abstract:
Objective To investigate the value of combined determination of plasma BNP, PDW and RDW in patients with chronic heart failure.Methods 100 patients with chronic heart failure admitted to our hospital from August 2019 to July 2020 were selected as the study group. According to the New York Heart Association (NYHA) cardiac function classification, they were divided into grade II (n=42), grade III (n=36) and grade IV (n=22). According to the principle of 1:1 matching, 100 healthy volunteers who came to our hospital for physical examination were selected as the control group.The plasma levels of BNP, PDW, and RDW in each group were compared, and their correlation with the cardiac function classification of patients with chronic heart failure was analyzed.Results The levels of plasma BNP, PDW, and RDW in the study group were higher than those in the control group,the difference was statistically significant (P<0.05);The plasma BNP, PDW, and RDW levels of the Ⅱ, Ⅲ and Ⅳ groups were compared,the difference was statistically significant (P<0.05).Pearson correlation analysis showed that plasma BNP, PDW, RDW levels were positively correlated with the cardiac function classification of patients with chronic heart failure (r=0.861,0.584,0.474,P<0.05).Conclusion Plasma levels of BNP, PDW and RDW are positively correlated with the cardiac function classification of patients with chronic heart failure, and show an increasing trend with the increase of the cardiac function classification of patients with chronic heart failure, which has certain significance in the diagnosis, condition and evaluation of heart function in patients with chronic heart failure value.

参考文献/References:

[1]周坤,王亚玲,张国茹.血清BNP水平在心力衰竭分级中的预后及诊断意义[J].中国实验诊断学,2020,24(6):895-899. [2]Ponikowski P,Voors AA,Anker SD,et al.ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200. [3]刘赛磊,张雪娥,靳妮,等.血清脑啡肽酶与慢性心力衰竭的相关性研究[J].中国循证心血管医学杂志,2020,12(6):748-751. [4]Almufleh A,Marbach J,Chih S,et al.Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients[J].Am J Cardiovasc Dis,2017,7(6):108-113. [5]Ibrahim NE,Gaggin HK,Rabideau DJ,et al.Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study[J].J Card Fail,2017,23(2):121-130. [6]李志强,傅咏华,王春燕,等.联合多项自检参数对慢性心力衰竭患者管理的作用[J].中华全科医学,2018,16(7):1128-1132. [7]唐红秀,王璐,万楠,等.慢性心力衰竭患者外周血RDW与HDL-C水平的相关性分析[J].现代检验医学杂志,2018,33(6):88-90,94. [8]贾凯剑,郭任维,高胜利,等.红细胞分布宽度与慢性心力衰竭的相关性研究[J].中国现代医学杂志,2019,29(24):27-31. [9]Ryo I,Yusuke U,Takahiro O,et al.Impact of red blood cell distribution width on non-cardiac mortality in patients with acute decompensated heart failure with preserved ejection fraction[J].Journal of cardiology,2017,70(5):591-597. [10]李硕,黎百志,李晓慧,等.血清红细胞分布宽度尿酸和脑钠肽联合检测在诊断慢性心力衰竭中的临床价值[J].河北医学,2019,25(5):841-844. [11]刘晶,李英梅,刘欣艳,等.红细胞分布宽度与慢性心力衰竭患者心功能指标的相关性研究[J].中国预防医学杂志,2017,18(5):330-333. [12]朱春海,倪晓媚,卢益中.慢性心力衰竭患者红细胞分布宽度与室性心动过速,心室扑动/心室颤动的相关性分析[J].心电与循环,2015,34(6):440-442,446. [13]强丽,吴刚,秦娇.基于炎症因子中性粒/淋巴细胞比值及红细胞分布宽度建立乙肝相关慢加急性肝衰竭预后的新型预测模型[C]//第十届全国疑难及重症肝病大会论文汇编.2019. [14]张冬花,李志忠,张京梅,等.红细胞分布宽度与冠心病患者经皮冠状动脉介入治疗术后支架内再狭窄的相关性研究[J].中国综合临床,2017,33(12):1084-1088. [15]丁心悦,刘开琦,赵文华.营养对炎症因子或氧化应激等人体免疫相关生物标记物的影响[J].中华医学杂志,2020,100(48):3897-3902.

相似文献/References:

[1]贺明清,刘孝娅.环磷腺苷葡胺治疗慢性心力衰竭临床疗效观察[J].医学信息,2018,31(10):135.[doi:10.3969/j.issn.1006-1959.2018.10.045]
　HE Ming-qing,LIU Xiao-ya.Clinical Efficacy of Cyclic Adenosine Glucosamine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(02):135.[doi:10.3969/j.issn.1006-1959.2018.10.045]
[2]李鹏飞,何荣华,王琼涛,等.单胺氧化酶对老年心力衰竭患者临床应用价值[J].医学信息,2018,31(17):78.[doi:10.3969/j.issn.1006-1959.2018.17.023]
　LI Peng-fei,HE Rong-hua,WANG Qiong-tao,et al.Clinical Value of Monoamine Oxidase in Elderly Patients with Heart Failure[J].Medical Information,2018,31(02):78.[doi:10.3969/j.issn.1006-1959.2018.17.023]
[3]曹 云,李树茂,裘 冬,等.益气温阳中药治疗慢性舒张性心力衰竭的疗效观察[J].医学信息,2019,32(01):162.[doi:10.3969/j.issn.1006-1959.2019.01.051]
　CAO Yun,LI Shu-mao,QIU Dong,et al.Therapeutic Effect of Yiqiwenyang Chinese Medicine on Chronic Diastolic Heart Failure[J].Medical Information,2019,32(02):162.[doi:10.3969/j.issn.1006-1959.2019.01.051]
[4]韩婷婷,王 虹,吴美美,等.N-proBNP对慢性心衰患者发生肺动脉高压的预测价值[J].医学信息,2019,32(05):114.[doi:10.3969/j.issn.1006-1959.2019.05.035]
　HAN Ting-ting,WANG Hong,WU Mei-mei,et al.Predictive Value of N-proBNP for Pulmonary Hypertension in Patients with Chronic Heart Failure[J].Medical Information,2019,32(02):114.[doi:10.3969/j.issn.1006-1959.2019.05.035]
[5]李 月,胡 雅,曹春乐,等.慢性心力衰竭患者健康心理控制源与自我管理的相关性研究[J].医学信息,2019,32(05):133.[doi:10.3969/j.issn.1006-1959.2019.05.042]
　LI Yue,HU Ya,CAO Chun-le,et al.Correlation between Health Psychological Control Sources and Self-management in Patients with Chronic Heart Failure[J].Medical Information,2019,32(02):133.[doi:10.3969/j.issn.1006-1959.2019.05.042]
[6]张文波,杨玉雯.希氏束起搏在慢性心力衰竭患者中的应用[J].医学信息,2019,32(10):41.[doi:10.3969/j.issn.1006-1959.2019.10.015]
　ZHANG Wen-bo,YANG Yu-wen.Application of His Bundle Pacing in Patients with Chronic Heart Failure[J].Medical Information,2019,32(02):41.[doi:10.3969/j.issn.1006-1959.2019.10.015]
[7]张凤娜,高伟勤.6min步行试验训练对慢性心力衰竭患者心功能的影响[J].医学信息,2019,32(16):97.[doi:10.3969/j.issn.1006-1959.2019.16.030]
　ZHANG Feng-na,GAO Wei-qin.The Effect of 6min Walking Test Training on Cardiac Function in Patients with Chronic Heart Failure[J].Medical Information,2019,32(02):97.[doi:10.3969/j.issn.1006-1959.2019.16.030]
[8]蒲军亮,张 婷.沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性心力衰竭的疗效观察[J].医学信息,2020,33(14):159.[doi:10.3969/j.issn.1006-1959.2020.14.051]
　PU Jun-liang,ZHANG Ting.Observation of Sacubitril Valsartan Sodium Tablets Combined with Metoprolol Succinate Sustained-release Tablets in the Treatment of Chronic Heart Failure[J].Medical Information,2020,33(02):159.[doi:10.3969/j.issn.1006-1959.2020.14.051]
[9]杜蔚蓓,张建伟.CHF患者血清甲状腺激素异常及小剂量左甲状腺素钠治疗的效果[J].医学信息,2020,33(15):73.[doi:10.3969/j.issn.1006-1959.2020.15.023]
　DU Wei-bei,ZHANG Jian-wei.Serum Thyroid Hormone Abnormalities in CHF Patients and the Effect of Low-dose Levothyroxine Sodium Therapy[J].Medical Information,2020,33(02):73.[doi:10.3969/j.issn.1006-1959.2020.15.023]
[10]袁 超.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的效果[J].医学信息,2020,33(19):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
　YUAN Chao.Effect of Sacubitril Valsartan Combined with Bisoprolol in the Treatment of Chronic Heart Failure[J].Medical Information,2020,33(02):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]

更新日期/Last Update: 1900-01-01